Assessment of Withdrawal Symptoms After Discontinuation of AXS-05 (Dextromethorphan-Bupropion) Treatment: Results From the GEMINI Trial


Rakesh Jain, MD, MPH¹; Caroline Streicher, BA²; Amanda Jones, PharmD^{2*}; Sucharita Somkuwar, PhD²; Zachariah Thomas, PharmD, MPH²; Herriot Tabuteau, MD²

¹Texas Tech University – Permian Basin, Midland, TX, USA; ²Axsome Therapeutics, New York, NY, USA

Introduction

- Traditional oral antidepressants act primarily via the monoamine pathway¹, and can be associated with withdrawal effects upon discontinuation in up to 56% of patients²
- As a class, antidepressants are associated with a higher risk of withdrawal symptoms compared with other medications³
- Antidepressant withdrawal symptoms can be wide ranging and include flu-like symptoms, insomnia, nausea, imbalance, sensory disturbances, and hyperarousal (eg, anxiety and agitation)⁴
- Among those experiencing withdrawal symptoms, nearly half (46%) rate these symptoms as severe²
- In an analysis of more than 20,000 cases of antidepressant withdrawal, the most frequently reported symptoms were dizziness (13.13%), nausea (9.48%), paresthesia (8.30%), headache (7.35%), and anxiety (5.72%)³

AXS-05: A Novel, Oral NMDA Receptor Antagonist With Multimodal Activity



- AXS-05 [dextromethorphan-bupropion (Auvelity[®] extended-release tablet)] is a novel, oral, *N*-methyl-*D*-aspartate (NMDA) receptor antagonist with multimodal activity approved by the United States Food and Drug Administration for the treatment of major depressive disorder (MDD) in adults⁵
- The dextromethorphan component of AXS-05 is an antagonist of the NMDA receptor (an ionotropic glutamate receptor) and a sigma-1 receptor agonist^{5,6}
- The bupropion component of AXS-05 is an aminoketone and CYP450 2D6 inhibitor, which serves primarily to increase the bioavailability of dextromethorphan and is a norepinephrine and dopamine reuptake inhibitor^{5,6}
- The efficacy and safety of AXS-05 in patients with MDD have been previously established⁵⁻⁷; however, assessment of potential withdrawal symptoms upon discontinuation of AXS-05 in MDD has not been previously reported

Objective


To evaluate potential withdrawal symptoms following discontinuation of AXS-05 without taper compared with placebo in patients with MDD using the 20-item Physician Withdrawal Checklist (PWC-20)

Methods

GEMINI was a 6-week, randomized, double-blind, placebo-controlled trial (NCT04019704) conducted from June 20, 2019, to December 5, 2019, at 40 sites in the United States^{6,8}

Key Inclusion / Exclusion Criteria		
Inclusion	Exclusion	
 Adults aged 18–65 years DSM-5⁹ criteria for MDD without psychotic features MADRS¹⁰ total score ≥25 CGI-S¹¹ score ≥4 at baseline 	 History of depressive episode with psychotic or catatonic features, treatment-resistant depression^a, schizophrenia, bipolar disorder, panic disorder, OCD, bulimia or anorexia nervosa, persistent neurocognitive disorder, or primary anxiety disorder Alcohol/substance use disorder within 1 year Clinically significant risk of suicide or harm to self or others Seizure disorder 	

^aDefined as 2 or more failed prior treatments of adequate dose and duration in the current depressive episode CGI-S, Clinical Global Impression-Severity; DSM-5, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; OCD, obsessive compulsive disorder.




	Physician Withdrawal C	
<u>Category</u>	<u>Symptoms</u>	
Cognitive	Poor coordination; dizziness/ smell, touch, pain; depersona	
Fatigue	Fatigue/lethargy/lack of ener	
Gastrointestinal	Loss of appetite; nausea/von	
Mood	Anxiety/nervousness; irritabi restlessness/agitation; difficu	
Somatic	Insomnia; diaphoresis; tremo or stiffness	

Baseline Demographic and Clinical Characteristics^a

Buschne Demographie and enheat enaluetensities			
Characteristic	AXS-05 (n=156)	Placebo (n=162)	
Demographic characteristics			
Age, years, mean (SD)	42.1 (12.8)	41.2 (13.8)	
Sex (female), n (%)	95 (60.9)	117 (72.2)	
Race, n (%)			
White	84 (53.8)	92 (56.8)	
Black or African American	58 (37.2)	54 (33.3)	
Asian	9 (5.8)	8 (4.9)	
Multiple	3 (1.9)	2 (1.2)	
Other	2 (1.3)	6 (3.7)	
BMI, kg/m ² , mean (SD)	29.3 (5.61)	29.3 (5.69)	
Clinical characteristics			
MADRS total score ^b , mean (SD)	33.6 (4.43)	33.2 (4.36)	
CGI-S score ^c , mean (SD)	4.6 (0.59)	4.6 (0.57)	

^aModified intent-to-treat population. ^bMADRS scores range from 0–60, with higher scores indicating more severe depression. ^cCGI-S scores range from 1-7, with higher scores representing more severe disease. BMI, body mass index; CGI-S, Clinical Global Impression-Severity; MADRS, Montgomery-Åsberg Depression Rating Scale; SD, standard deviation.

Baseline disease severity demonstrated the patient population had moderate to severe depression; demographics were generally similar across treatment groups



The severity of dizziness/lightheadedness and nausea/vomiting following discontinuation of AXS-05 was mild or moderate in 92% (n=23/25) and 88% (n=14/16), respectively, of patients reporting these symptoms

References: 1. Machado-Vieira R, et al. Prog Neurobiol. 2017;152:21-37. 2. Davies J, Read J. Addict Behav. 2018;97:111-21. 3. Gastaldon C, et al. Prog Neurobiol. 2017;152:21-37. 2. Davies J, Read J. Addict Behav. 2018;97:111-21. 3. Gastaldon C, et al. Prog Neurobiol. 2017;152:21-37. 2. Davies J, Read J. Addict Behav. 2018;97:111-21. 3. Gastaldon C, et al. Prog Neurobiol. 2017;152:21-37. 2. Davies J, Read J. Addict Behav. 2018;97:111-21. 3. Gastaldon C, et al. Prog Neurobiol. 2017;152:21-37. 2. Davies J, Read J. Addict Behav. 2018;97:111-21. 3. Gastaldon C, et al. Prog Neurobiol. 2017;152:21-37. 2. Davies J, Read J. Addict Behav. 2018;97:111-21. 3. Gastaldon C, et al. Prog Neurobiol. 2017;152:21-37. 2. Davies J, Read J. Addict Behav. 2018;97:111-21. 3. Gastaldon C, et al. Prog Neurobiol. 2017;152:21-37. 2. Davies J, Read J. Addict Behav. 2018;97:111-21. 3. Gastaldon C, et al. Prog Neurobiol. 2017;152:21-37. 2. Davies J, Read J. Addict Behav. 2018;97:111-21. 3. Gastaldon C, et al. Prog Neurobiol. 2017;152:21-37. 2. Davies J, Read J. Addict Behav. 2018;97:111-21. 3. Gastaldon C, et al. Prog Neurobiol. 2017;152:21-37. 2. Davies J, Read J. Addict Behav. 2018;97:111-21. 3. Gastaldon C, et al. Prog Neurobiol. 2017;152:21-37. 2. Davies J, Read J. Addict Behav. 2018;97:111-21. 3. Gastaldon C, et al. Prog Neurobiol. 2017;152:21-37. 2. Davies J, Read J. Addict Behav. 2018;97:111-21. 3. Gastaldon C, et al. Prog Neurobiol. 2017;152:21-37. 2. Davies J, Read J. Addict Behav. 2018;97:111-21. 3. Gastaldon C, et al. Prog Neurobiol. 2017;152:21-37. 2. Davies J, Read J, Addict Behav. 2018;97:111-21. 3. Gastaldon C, et al. Prog Neurobiol. 2017;152:21-37. 2. Davies J, Read J, Addict Behav. 2018;97:111-21. 3. Gastaldon C, et al. Prog Neurobiol. 2017;152:21-37. 2. Davies J, Read J, Addict Behav. 2018;97:111-21. 3. Gastaldon C, et al. Prog Neurobiol. 2017;152:21-37. 2. Davies J, Read J, Addict Behav. 2018;97:111-21. 3. Gastaldon C, et al. Prog Neurobiol. 2017;152:21-37. 2. Davies J, Read J, Addict Behav. 2018;97:111-21. 3. Gastaldon C, 2022. 6. losifescu DV, et al. J Clin Psychiatry. 2022;83(4):e1-e9. 7. Tabuteau H, et al. Am J Psychiatry. 2022;179(7):490-9. 8. A Trial of AXS-05 in Patients With Major Depressive Disorder (GEMINI) NCT04019704. 2022. Available at: https://clinicaltrials.gov/ct2/show/NCT04019704. Accessed: 11 April 2023. 9. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013:160-8. 10. Montgomery SA, Åsberg M. Br J Psychiatry. 1979;134:382-9. 11. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised. Rockville MD: U.S. Department of Health, Education, and Welfare; 1976. 12. Rickels K, et al. J Clin Psychopharmacol. 2008;28(4):447-51. Disclosures: R. Jain is a consultant to Axsome. C. Streicher, Z. Thomas, and H. Tabuteau are current employees of Axsome Therapeutics. A. Jones is no longer affiliated with Axsome. Acknowledgments: This study was funded by Axsome Therapeutics. Jacob Huffman, PhD, of Peloton Advantage, LLC, an OPEN Health company, provided medical writing and editorial support for this poster, which was funded by Axsome Therapeutics.



Axsome Therapeutics 1 World Trade Center, 22nd Floor New York, NY 10007

Conclusions

- Following 6 weeks of treatment, discontinuation of AXS-05 without taper was well tolerated as evaluated by the PWC-20, with similar rates across most symptoms when compared with placebo
- Only 2 of 20 symptoms occurred more frequently in patients treated with AXS-05 than with placebo, and most of those symptoms were reported as mild in severity
- These data expand on existing efficacy and safety findings of AXS-05, and suggest that AXS-05 can be discontinued without taper with limited withdrawal effects after 6 weeks of treatment
- The rates of withdrawal symptoms in the placebo group were notable and were numerically higher than the AXS-05 group in several instances, highlighting the need for controlled data when studying withdrawal symptoms

Scan QR code or access https://www.axsomecongresshub.com/NEI2023 to view or download a PDF of this poster or access additional information and other Axsome Therapeutics presentations at NEI 2023

